Fourth ICMC International Congress, New York 2024

---

PROGRAM

8:30- 8:45
Welcome and Introduction by the Population Council and ICMC
Jim Sailer (USA), Regine Sitruk-Ware (USA/FR), David Serfaty (FR)
 

Session 1: NEW FIELDS OF RESEARCH

Chair: Philippe Bouchard (FR), Jim Sailer (USA)

8:45 – 09:30
Selective Retinoic Acid Receptor Alpha Antagonist
Chemistry approach: Gunda Georg (USA)
Proof-of Concept in in vivo models: Debra Wolgemuth (USA)

09:30 – 10:00
Soluble Adenyl Cyclase (sAC). Progress in development
Jochen Buck & Lonny Levin (USA) (Cornell, USA)

10:00 – 10:25
Update on Male Contraceptive Initiative Activities in progress
Logan Nickels, MCI (USA)

10:25 – 10:45
Clinical development of YCT 529. Inhibitor of retinoic acid receptor-alpha
Akash Bakshi (USA)

10:45 – 11:00 Break

Session 2: HORMONAL METHODS

Chair: David Archer (USA), Mitch Creinin (USA)

11:00 – 11:30
NES/T transdermal gel efficacy study
Christina Wang (USA)

11:30 – 12:00p
Novel Androgens for Male Contraception
Stephanie Page (USA)

12:00p – 12:30p
Novel Androgens for Male Contraception
Stephanie Page (USA)

12:30 – 13:30 Lunch

Session3: BEHAVIORAL ASPECTS OF MALE CONTRACEPTION

Chair: Ronald Swerdloff (USA), Stephanie Page (USA)

13:30 – 14:00
Male Contraception potential impact on Global Reproductive Health
Nancy Kidula (WHO, CH)

14:00 – 14:30
Demand for male contraceptives: Landscape
Steve Kretschmer (DesireLine) (USA)

14:30 – 14:45 (ISA-sponsored Abstract)
Population differences in responses to Male Hormonal Contraception (Lessons Learned from the WHO-CONRAD phase III study)
Michael Zitzmann (DE)

Session 4: NEW APPROACHES TO MALE CONTRACEPTION

Chair: Richard Anderson (UK), William Bremner (USA), Peter Liu (USA)

14:45 – 15:15
PANEL on Guidelines for Male Contraception Studies
Practice and Development of Male Contraception- EAA-ISA Guidelines
Christina Wang (USA), Stanton Honig (USA) and Cristina Meriggiola (IT)

15:15 – 15:30 Break

15:30 – 16:00
Non-hormonal methods: Landscape
J. Amory (USA)

16:00 – 16:30
Update of ADAM, a vas-occlusive hydrogel device
Kevin Eisenfrats (USA)

16:30 – 16:45 (Abstract)
Plan A: Non-Hormonal Vas Occlusion
Charles Carignan (USA)

Session 5: ROLE OF THE COLLABORATIVE AGENCIES

Chair: Kristina Gemzell (SE), Cristina Meriggiola (IT)

16:45 – 17:30
Panel discussion: Mark Barone (BMGF), Diana Blithe (NICHD), Laneta Dorflinger (FHI360), Nancy Kidula (WHO), Heather Vahdat (MCI), Jim Sailer (Population Council)

Session 6: GENERAL DISCUSSION

Chairs: Regine Sitruk-Ware (USA/FR), David Serfaty (FR)

17:30 – 18:00
Timeline from Development to Market for male contraceptives, Conclusions
Stephanie Page (USA), Diana Blithe (NICHD, USA)

18:15 – 19:15
Wine and Cheese Cocktail Party

 

Organizing Scientific Committee: Diana Blithe, Philippe Bouchard, Kristina Gemzell-Danielsson, Eberhard Nieschlag, David Serfaty, Regine Sitruk-Ware (Chair), Heather Vahdat, Christina Wang